New imaging agent studied for brain and pancreatic cancers
NCT ID NCT04712721
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study tested a new radioactive imaging agent called [68Ga]-FF58 to see how well it could detect certain solid tumors, including glioblastoma, breast cancer that spread to the brain, gastroesophageal cancer, and pancreatic cancer. The study was early-phase and involved 14 adults whose tumors were expected to have specific proteins. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.